Mutant P53 Mediates Survival of Breast Cancer Cells

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Sep 24

PMID 19773755

Citations 95

Authors

L Y Lim

N Vidnovic

L W Ellisen

C-O Leong

Affiliations

Soon will be listed here.

Abstract

Background: p53 is the most commonly mutated tumour-suppressor gene in human cancers. Unlike other tumour-suppressor genes, most p53 cancer mutations are missense mutations within the core domain, leading to the expression of a full-length mutant p53 protein. Accumulating evidence has indicated that p53 cancer mutants not only lose tumour suppression activity but also gain new oncogenic activities to promote tumourigenesis.

Methods: The endogenous mutant p53 function in human breast cancer cells was studied using RNA interference (RNAi). Gene knockdown was confirmed by quantitative PCR and western blotting. Apoptosis was evaluated by morphological changes of cells, their PARP cleavage and annexin V staining.

Results: We show that cancer-associated p53 missense mutants are required for the survival of breast cancer cells. Inhibition of endogenous mutant p53 by RNAi led to massive apoptosis in two mutant p53-expressing cell lines, T47D and MDA-MB-468, but not in the wild-type p53-expressing cells, MCF-7 and MCF-10A. Reconstitution of an RNAi-insensitive mutant p53 in MDA-MB-468 cells completely abolished the apoptotic effects after silencing of endogenous mutant p53, suggesting the specific survival effects of mutant p53. The apoptotic effect induced by mutant p53 ablation, however, is independent of p63 or p73 function.

Conclusion: These findings provide clear evidence of a pro-survival 'gain-of-function' property of a subset of p53 cancer mutants in breast cancer cells.

Citing Articles

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type.

Rahme R, Resnick-Silverman L, Anguiano V, Campbell M, Fenaux P, Manfredi J EMBO Rep. 2025; 26(5):1315-1343.

PMID: 39875582 PMC: 11893899. DOI: 10.1038/s44319-025-00375-y.

An Expanded Registry of Candidate cis-Regulatory Elements for Studying Transcriptional Regulation.

Moore J, Pratt H, Fan K, Phalke N, Fisher J, Elhajjajy S bioRxiv. 2025; .

PMID: 39763870 PMC: 11703161. DOI: 10.1101/2024.12.26.629296.

Sodium arsenite-induced DNA methylation alterations exacerbated by p53 knockout in MCF7 cells.

Chung F, Khoueiry R, Salle A, Cuenin C, Boskovic M, Herceg Z Heliyon. 2024; 10(21):e39548.

PMID: 39512451 PMC: 11539298. DOI: 10.1016/j.heliyon.2024.e39548.

P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells.

Sun D, Yoon J, Kim Y, Won H Cancer Genomics Proteomics. 2024; 21(5):511-522.

PMID: 39191497 PMC: 11363922. DOI: 10.21873/cgp.20468.

A case report and literature review on TP53 gene mutation in a bladder rhabdomyosarcoma patient.

Li Y, Yang T, Zheng Z, Wang Z, Umar S, Fan N Front Oncol. 2024; 14:1396368.

PMID: 39139286 PMC: 11319136. DOI: 10.3389/fonc.2024.1396368.

References

Aas T, Borresen A, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug J . Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996; 2(7):811-4. DOI: 10.1038/nm0796-811. View

Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower L . A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 1995; 9(3):305-11. DOI: 10.1038/ng0395-305. View

Selivanova G . p53: fighting cancer. Curr Cancer Drug Targets. 2004; 4(5):385-402. DOI: 10.2174/1568009043332934. View

Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L . Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem. 2000; 275(38):29503-12. DOI: 10.1074/jbc.M003360200. View

Yang A, Kaghad M, Caput D, McKeon F . On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 2002; 18(2):90-5. DOI: 10.1016/s0168-9525(02)02595-7. View

Graeber T, Osmanian C, Jacks T, Housman D, Koch C, Lowe S . Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379(6560):88-91. DOI: 10.1038/379088a0. View

Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M . Gain of function mutations in p53. Nat Genet. 1993; 4(1):42-6. DOI: 10.1038/ng0593-42. View

Davis B, Dong Y, Weiss R . Overexpression of p73 causes apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2002; 284(1):C16-23. DOI: 10.1152/ajpcell.00211.2002. View

Lang G, Iwakuma T, Suh Y, Liu G, Rao V, Parant J . Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861-72. DOI: 10.1016/j.cell.2004.11.006. View

10.

Lotem J, Sachs L . A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. Proc Natl Acad Sci U S A. 1995; 92(21):9672-6. PMC: 40864. DOI: 10.1073/pnas.92.21.9672. View

11.

Murphy K, Dennis A, Rosen J . A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 2000; 14(14):2291-302. DOI: 10.1096/fj.00-0128com. View

12.

Nelson W, Kastan M . DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 1994; 14(3):1815-23. PMC: 358539. DOI: 10.1128/mcb.14.3.1815-1823.1994. View

13.

Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J . Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994; 145(3):702-14. PMC: 1890319. View

14.

Liu G, McDonnell T, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar A . High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000; 97(8):4174-9. PMC: 18187. DOI: 10.1073/pnas.97.8.4174. View

15.

Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C . A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001; 21(5):1874-87. PMC: 86759. DOI: 10.1128/MCB.21.5.1874-1887.2001. View

16.

Marin M, Jost C, Brooks L, Irwin M, ONions J, Tidy J . A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000; 25(1):47-54. DOI: 10.1038/75586. View

17.

Milner J, Medcalf E, Cook A . Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol. 1991; 11(1):12-9. PMC: 359578. DOI: 10.1128/mcb.11.1.12-19.1991. View

18.

Kim E, Deppert W . Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem. 2004; 93(5):878-86. DOI: 10.1002/jcb.20271. View

19.

Lowe S, Ruley H . Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993; 7(4):535-45. DOI: 10.1101/gad.7.4.535. View

20.

Birch J, Blair V, Kelsey A, Evans D, Harris M, Tricker K . Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998; 17(9):1061-8. DOI: 10.1038/sj.onc.1202033. View